COLLEEN BATES: Open Payments
NPI 1255015459 · GENEVA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 8 payments from 7 companies in 2025. Trend: 2023 $39 · 2024 $114 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $130 |
| Alkermes, Inc. | 2 | $119 |
| E.R. Squibb & Sons, L.L.C. | 1 | $102 |
| ABBVIE INC. | 1 | $93 |
| Axsome Therapeutics, Inc. | 1 | $86 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: CAPLYTA, LYBALVI, COBENFY, VRAYLAR, Auvelity, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across OH — which companies pay providers there.
